How Is Croda International Plc (LSE:CRDA) Trading Today?

Croda International Plc (LSE:CRDA) shares edged higher by 0.03% to around 3,759.0p today, following a third-quarter trading update on 5 November 2026 that confirmed the group's full-year outlook.

Group sales were £449.9 million, an organic increase of 6.6%, ahead of the group's medium-term range. Consumer Care delivered organic growth of 10.8%, with beauty actives up 19% and beauty care up 13%.

The company said it is on track to deliver its 2026 outlook and the financial framework it set for 2028.

About Croda International Plc

Croda is a specialty chemicals company founded in 1925 that creates ingredients for beauty, personal care, home care, pharmaceuticals, crop protection and industrial applications. Its three divisions are Consumer Care, Life Sciences and Industrial Specialties.

The group draws on science-led innovation and bio-based raw materials to help customers develop effective, sustainable products.

LSE:CRDA therefore offers exposure to Long-term Growth in beauty, health and sustainable chemistry.

Q3 2026 Trading

Consumer Care sales of £266.3 million rose 10.2% as reported, with both volumes and price and mix positive. Home care sales rose 10%, and beauty innovation supported Demand from global brands. Life Sciences sales of £135.2 million grew 1.8% organically, with pharma up 5% and seed enhancement up 12%.

Asia was the best-performing region with 12% organic growth, while EMEA grew 6% and North America 4%.

Management said the growth in beauty was supported by increased innovation activity, with new actives and formulations introduced to global brands. Seed enhancement and pharma also contributed to Life Sciences, while Crop Protection faced a demanding comparison with the prior year.

Outlook and Framework

For 2026, Croda continues to expect Organic Sales growth of 3% to 6% and a further improvement in adjusted operating margin, supported by better profitability in Consumer Care and Life Sciences and the benefits of its transformation programme.

The group targets an adjusted Operating Margin above 20% by 2028, with around £100 million of annualised pre-tax benefits and a reduction of around £50 million in Working Capital by the same year. Further incremental savings are expected in the second half of 2026 and in 2027.

The group said it is increasing prices where necessary to recover input costs and that the Middle East region represented roughly 5% of sales, mainly in fragrances and flavours, with no material effect on the Business in the first quarter.

Prior Year Performance

For the year to 31 December 2025, adjusted operating profit rose 5.6% to £295.3 million and the adjusted operating margin improved to 17.4% from 17.2%. Net Debt was £524 million, and the total Dividend was 111p per share, with the final dividend at 63p.

Croda has increased its annual dividend for more than 20 consecutive years.

Strategy in Action

Management described a plan to refocus innovation, make use of customer proximity, reinvigorate Beauty, rebalance Pharma and maximise returns from recent investments. Sales resource is being directed to key customer segments where it creates the greatest value.

Management noted that fourth-quarter sales are expected to be seasonally lower than the third quarter as some customers manage working capital into the year end.

Pharma activity centres on lipid systems and adjuvants used in advanced medicines, an area where the company has built a leading position over many years of innovation-led development. Management has described Investment in new capacity as an enabler of future growth.

Growth Catalysts

Possible catalysts for LSE:CRDA include continued beauty innovation, pharma delivery systems for new medicines, seed enhancement, further efficiency gains and growing demand in Asia.

The company's expertise in lipid systems and its portfolio of sustainable ingredients also position it for demand linked to health and wellbeing.

Consumers' interest in ingredients with proven efficacy and a lower environmental footprint plays to the group's strengths in bio-based chemistry, and a close relationship with Brand owners helps it respond quickly to changing trends.

The group's focus on sustainable ingredients, formulation expertise and close customer collaboration provides a route to long-term growth in personal care, life sciences and consumer markets. Investment in bio-based chemistry and delivery technologies aims to support differentiated products.

Factors to Monitor

Specialty chemical results are influenced by customer inventory decisions, raw material costs, currency movements and demand in agricultural markets. Quarterly sales can vary with order timing.

Investors typically follow organic sales growth, margins, cost savings and net debt.

Conclusion

Croda's small gain to around 3,759.0p today follows a third quarter of 6.6% organic sales growth led by beauty, with the 2026 outlook confirmed.

Beauty innovation, pharma, Asia and the 2028 financial framework remain the central themes for LSE:CRDA.

For those following LSE:CRDA, Volume trends, innovation progress and margin delivery will remain the key reference points through the coming periods.